Blueprint Medicines Corp (BPMC) receives a strong valuation ranking of 78 from InvestorsObserver's data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. BPMC has a better value than 78% of stocks based on these valuation analytics. Investors primarily focused on buy-and-hold strategies will find the valuation ranking relevant to their goals when making investment decisions.
Metrics Analysis
BPMC has a trailing twelve month Price to Earnings (PE) ratio of 20.6. The historical average of roughly 15 shows a poor value for BPMC stock as investors are paying higher share prices relative to the company's earnings. BPMC's high trailing PE ratio shows that the firm has been trading above its fair market value recently. Its trailing 12-month earnings per share (EPS) of 5.44 does not justify the stock's current price. However, trailing PE ratios do not factor in the company's projected growth rate, resulting in many newer firms having high PE ratios due to high growth potential enticing investors despite inadequate earnings.
BPMC currently has a 12-month-forward-PE-to-Growth (PEG) ratio of 0.63. The market is currently undervaluing BPMC in relation to its projected growth due to the PEG ratio being below the fair market value of 1. BPMC's PEG comes from its forward price to earnings ratio being divided by its growth rate. Because PEG ratios include more fundamentals of a company's overall health with additional focus on the future, they are one of the most used valuation metrics by analysts.
Summary
BPMC' has a strong valuation at its current share price on account of a undervalued PEG ratio despite strong growth. BPMC's PE and PEG are better than the market average leading to a above average valuation score.
Click Here to get the full Stock Score Report on Blueprint Medicines Corp (BPMC) Stock.
